<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303549</url>
  </required_header>
  <id_info>
    <org_study_id>GESITRA 0110</org_study_id>
    <secondary_id>2011-000804-17</secondary_id>
    <nct_id>NCT01303549</nct_id>
  </id_info>
  <brief_title>Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients</brief_title>
  <acronym>AVALTRA</acronym>
  <official_title>Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, open-label safety study comparing the use of anidulafungin (200 mg
      i.v. as initial dose and 100 mg/d i.v. in subsequent doses) vs liposomal amphotericin B (3
      mg/kg/d i.v.) in hepatic transplant recipients who have high risk of fungal infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal impairment/renal function deterioration</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the development of renal imparment or deterioration of baseline renal function in hepatic transplat recipients who receive anidulafungin or liposomal amphotericin B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusion related adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the development of infusion related adverse events in hepatic transplat recipients who receive anidulafungin or liposomal amphotericin B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuation</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the proportion of patiens who discontinue antifungal profilaxis in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic toxicity</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the emergence of hepatic toxicity in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive fungal infection</measure>
    <time_frame>Week 12 and week 24</time_frame>
    <description>Compare the incidence of early (first 12 weeks) and delayed (until week 24) invasive fungal infection between both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 weeks post transplantation</time_frame>
    <description>Compare the mortality rate (both global and fungal infection related) between both arms 24 weeks after transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Liver Disease</condition>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Anidulafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Amphotericin B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal amphotericin B once a day: 3 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anidulafungin</intervention_name>
    <description>Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.</description>
    <arm_group_label>Anidulafungin</arm_group_label>
    <other_name>Ecalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B</intervention_name>
    <description>Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.</description>
    <arm_group_label>Liposomal Amphotericin B</arm_group_label>
    <other_name>AmBisome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Signature of ICF

          -  Negative pregnancy test (women of child bearing potential)

          -  Patients who comply with at least one of the following (A or B):

        A: One of the following criteria (major criteria):

          -  Re-transplant due to severe dysfunction of a previous hepatic graft

          -  Requirement of any renal substitutive therapy, including dialysis or hemofiltration

          -  Fulminant hepatitis requiring hepatic transplant

        B: Two of the following criteria (minor criteria):

          -  Post-transplant renal impairment (defined as CrCl&lt; 50 mL/min) 30 days after
             transplantation

          -  Intra surgery blood transfusion of at least 40 units

          -  Choledochal jejunectomy

          -  2 or more Candida sp cultures (nasal, pharynx, rectal) from 48 hours pre- to 48 hours
             post-hepatic transplant

          -  Post transplant re-intervention (laparotomy)

        Exclusion Criteria:

          -  Hypersensibility to amphotericin B or candin

          -  Patients who have received any other antifungal (excluding fluconazole or oral
             nystatin for a maximum of 7 days)

          -  Documented or suspected fungal infection

          -  Pregnant women of women who do not accept to us a valid anticonceptive method

          -  Any other disease or medical condition that makes the patient not adequate to
             participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Cervera, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic i Provincial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asuncion Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Fariñas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de A Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Hepatic transplant</keyword>
  <keyword>Antifungal prophylaxis</keyword>
  <keyword>Anidulafungin</keyword>
  <keyword>Liposomal Amphotericin B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Anidulafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

